Author/Authors :
Hong، نويسنده , , Young Joon and Jeong، نويسنده , , Myung Ho and Hyun، نويسنده , , Dae Woo and Hur، نويسنده , , Seung Ho and Kim، نويسنده , , Kwon Bae and Kim، نويسنده , , Weon Cheol Lim، نويسنده , , Sang Yup and Lee، نويسنده , , Sang Hyun and Hong، نويسنده , , Seo Na and Kang، نويسنده , , Dong Goo and Yun، نويسنده , , Kyung Ho and Kim، نويسنده , , Kye Hun and Lee، نويسنده , , Yun-Sang and Park، نويسنده , , Hyung Wook and، نويسنده ,
Abstract :
We prospectively followed 202 patients with ischemic heart failure who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (left ventricular [LV] ejection fraction <40%). Patients were divided into 2 groups: groups I (simvastatin group, n = 106, aged 60.8 ± 10.3 years, men 71.7%) and II (non-simvastatin group, n = 96, aged 60.9 ± 10.4 years, men 78.1%). During 1-year clinical follow-up, simvastatin therapy was associated with a significant reduction in mortality (1.9% vs 7.5%, p = 0.048), restenosis rate (25.7% vs 43.1%, p = 0.033), and repeat PCI rate (25.7% vs 43.1%, p = 0.033), and with significant improvement in LV ejection fraction (31% to 42% vs 32% to 39%, p = 0.042). The event-free survival rate was higher in group I than in group II (79.8% vs 57.0%, p = 0.001). In conclusion, simvastatin therapy improves LV systolic function and decreases mortality, restenosis, and repeat PCI rate in patients with ischemic heart failure who underwent PCI for acute myocardial infarction.
